Deutsche Bank AG Decreases Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Deutsche Bank AG lessened its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,658 shares of the biopharmaceutical company's stock after selling 5,284 shares during the quarter. Deutsche Bank AG owned 0.20% of Madrigal Pharmaceuticals worth $13,472,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter worth approximately $70,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Madrigal Pharmaceuticals during the fourth quarter valued at $164,000. KBC Group NV boosted its holdings in Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock worth $188,000 after acquiring an additional 258 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth $210,000. Finally, Farringdon Capital Ltd. purchased a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth $215,000. 98.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director James M. Daly sold 15,470 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total value of $5,375,051.50. Following the transaction, the director now directly owns 1,912 shares in the company, valued at approximately $664,324.40. This represents a 89.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Robert E. Waltermire sold 14,113 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total transaction of $4,817,049.16. Following the completion of the sale, the vice president now directly owns 3,728 shares of the company's stock, valued at approximately $1,272,440.96. This trade represents a 79.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,810 shares of company stock valued at $10,610,594. Insiders own 21.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. B. Riley reaffirmed a "buy" rating and set a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. UBS Group upped their price target on shares of Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. JMP Securities reiterated a "market outperform" rating and set a $443.00 price target on shares of Madrigal Pharmaceuticals in a research note on Thursday, April 24th. HC Wainwright upped their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, StockNews.com upgraded Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $416.33.

Madrigal Pharmaceuticals Price Performance

Shares of Madrigal Pharmaceuticals stock traded down $0.24 during trading on Monday, reaching $290.72. 292,070 shares of the stock traded hands, compared to its average volume of 385,971. Madrigal Pharmaceuticals, Inc. has a 52-week low of $200.63 and a 52-week high of $377.46. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The business has a fifty day simple moving average of $317.98 and a two-hundred day simple moving average of $320.56. The company has a market capitalization of $6.45 billion, a price-to-earnings ratio of -11.59 and a beta of -0.91.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, topping analysts' consensus estimates of ($3.62) by $0.30. The business had revenue of $137.25 million during the quarter, compared to analysts' expectations of $112.79 million. During the same period in the previous year, the business earned ($7.38) earnings per share. Sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.